Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review
Open Access
- 31 December 2014
- Vol. 5 (4), e007746
- https://doi.org/10.1136/bmjopen-2015-007746
Abstract
Objectives: The aim of this study is to systematically review the evidence for anti-vascular endothelial growth factor (VEGF) therapy in choroidal neovascularisation secondary to conditions other than age-related macular degeneration. Data sources: MEDLINE, MEDLINE in-process, EMBASE and CENTRAL databases and conference abstracts were searched (from inception to Jan 2014). Study eligibility criteria, participants and interventions: Randomised and non-randomised comparative studies with follow-up of at least 6 months were included and were used to assess clinical effectiveness. Study appraisal and synthesis method: Risk of bias was assessed using the Cochrane risk of bias tool and modified Newcastle-Ottawa Scale. Meta-analysis was not possible due to methodological heterogeneity. Results: 16 studies met the inclusion criteria (1091 eyes; 963 pathological myopia, 74 other conditions). There was large variation in risk of bias across studies. An improvement in best-corrected visual acuity in anti-VEGF arms over comparators was reported in all studies. The proportion of patients improving by at least 15 letters in anti-VEGF arms ranged from 27.3% to 70%. There were no significant differences between bevacizumab and ranibizumab. Limitations: Owing to the rarity of choroidal neovascularisation secondary to conditions other than age-related macular degeneration or pathological myopia, there are unlikely to ever be sufficiently powered trials in these populations. Conclusions: Bevacizumab and ranibizumab appear to be effective in improving visual acuity for patients with choroidal neovascularisation secondary to conditions other than age-related macular degeneration. The evidence base is strongest for choroidal neovascularisation secondary to pathological myopia, however, based on current evidence and likely pharmacological pathways, clinicians should consider treatment with either bevacizumab or ranibizumab for rarer causes.This publication has 38 references indexed in Scilit:
- Protective Effects of Fufang Xueshuantong on Diabetic Retinopathy in RatsEvidence-Based Complementary and Alternative Medicine, 2013
- NON–FULL-THICKNESS MACULAR HOLES REASSESSED WITH SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHYRetina, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological MyopiaOphthalmologica, 2010
- Visual and Optical Coherence Tomography Outcomes of Intravitreal Bevacizumab and Ranibizumab in Inflammatory Choroidal Neovascularization Secondary to Punctate Inner ChoroidopathyEuropean Journal of Ophthalmology, 2010
- INTRAVITREAL ANTI-VEGF VERSUS PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2010
- Two-Year Visual Results for Older Asian Women Treated With Photodynamic Therapy or Bevacizumab for Myopic Choroidal NeovascularizationAmerican Journal of Ophthalmology, 2010
- Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisationBritish Journal of Ophthalmology, 2009
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- How blinding is pathological myopia?British Journal of Ophthalmology, 2006